In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A High-Profile Break Up

Executive Summary

The termination of PE Biosystem Group's acquisition of Third Wave Technologies has sprouted a number of unfounded rumors. But the reason seems to be what the companies initially said it was: A Department of Justice review of the merger for antitrust violations was taking longer than expected. With no end in sight to it and an uncertain outcome, the companies were losing business opportunities in a fast-moving field. Rather, they decided to continue to work together in an alliance, and have already established a joint venture that is one of the world's largest production facilities of oligonucleotides.

You may also be interested in...



Your Friend, the FTC: Nastech Solves a Knotty Anti-Trust Problem

When the FTC forced Pfizer/Pharmacia to divest Nastech's nasal apomorphine--a potential competitor of Pfizer's Viagra--Nastech managed what may be a unique solution: it got the product back, with additional financing-and in so doing, solved the very different problems of Pharmacia, Pfizer, the FTC, and itself.

EU Business Round-Up: Stada Enters Germany Top-5, Dr Wolff Takes Vagisan To Poland, Fidia And Sanova Strike Nasal Spray Deals

European Medicines Agency Commits To Promoting Real-World Data

The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID054590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel